Effectiveness and safety of isavuconazole prophylaxis for invasive fungal infections in the haematologic setting

References

• Drgona L, Khachatryan A, Stephens J, et al. Clinical and economic burden of invasive fungal diseases in Europe: focus on pre-emptive and empirical treatment of Aspergillus and Candida species. Eur J Clin Microbiol Infect Dis. 2014;33(1):7–21.
   PubMed Web of Science ®Google Scholar
• Menzin J, Meyers JL, Friedman M, et al. Mortality, length of hospitalization, and costs associated with invasive fungal infections in high-risk patients. Am J Health Syst Pharm. 2009;66(19):1711–1717.
   PubMed Web of Science ®Google Scholar
• Fleming S, Yannakou CK, Haeusler GM, et al. Consensus guidelines for antifungal prophylaxis in haematological malignancy and haemopoietic stem cell transplantation, 2014. Intern Med J. 2014;44(12b):1283–1297.
   PubMed Web of Science ®Google Scholar
• Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the Infectious Diseases Society of America. Clin Infect Dis. 2011;52(4):e56–93.
   PubMed Web of Science ®Google Scholar
• Maertens JA, Girmenia C, Brüggemann RJ, et al. European guidelines for primary antifungal prophylaxis in adult haematology patients: summary of the updated recommendations from the European Conference on Infections in Leukaemia. J Antimicrob Chemother. 2018;73(12):3221–3230.
   PubMed Web of Science ®Google Scholar
• Mellinghoff SC, Panse J, Alakel N, et al. Primary prophylaxis of invasive fungal infections in patients with haematological malignancies: 2017 update of the recommendations of the Infectious Diseases Working Party (AGIHO) of the German Society for Haematology and Medical Oncology (DGHO). Ann Hematol. 2018;97(2):197–207.
   PubMed Web of Science ®Google Scholar
• Ullmann AJ, Schmidt-Hieber M, Bertz H, et al. Infectious diseases in allogeneic haematopoietic stem cell transplantation: prevention and prophylaxis strategy guidelines 2016. Ann Hematol. 2016;95(9):1435–1455.
   PubMed Web of Science ®Google Scholar
• Zhao YJ, Khoo AL, Tan G, et al. Network meta-analysis and pharmacoeconomic evaluation of fluconazole, itraconazole, posaconazole, and voriconazole in invasive fungal infection prophylaxis. Antimicrob Agents Chemother. 2016;60(1):376–386.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration. Noxafil (posaconazole) prescribing information. 2015.
   Google Scholar
• European Medicines Agency Noxafil (posaconazole): summary of product characteristics. 2014.
   Google Scholar
• European Medicines Agency Vfend (voriconazole): summary of product characteristics. 2021.
   Google Scholar
• Salas MQ, Mussetti A, Muñóz C, et al. Isavuconazole prophylaxis against invasive fungal infections in allogeneic stem cell transplantation: a single-center experience [published online ahead of print February 8, 2021]. Hematol Transfus Cell Ther; doi:10.1016/j.htct.2021.01.002.
   Google Scholar
• Menna P, Salvatorelli E, Del Principe MI, et al. Choosing antifungals for the midostaurin-treated patient: does CYP3A4 outweigh recommendations? A brief insight from real life [published online ahead of print March 5, 2021]. Chemotherapy: doi:10.1159/000513989.
   Google Scholar
• European Medicines Agency Cresemba (isavuconazole): summary of product characteristics. 2019.
   Google Scholar
• US Food and Drug Administration Cresemba (isavuconazonium sulfate) prescribing information. 2019.
   Google Scholar
• Schmitt-Hoffmann A, Roos B, Heep M, et al. Single-ascending-dose pharmacokinetics and safety of the novel broad-spectrum antifungal triazole BAL4815 after intravenous infusions (50, 100, and 200 milligrams) and oral administrations (100, 200, and 400 milligrams) of its prodrug, BAL8557, in healthy volunteers. Antimicrob Agents Chemother. 2006;50(1):279–285.
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration Vfend (voriconazole) prescribing information. 2015.
   Google Scholar
• Xing Y, Chen L, Feng Y, et al. Meta-analysis of the safety of voriconazole in definitive, empirical, and prophylactic therapies for invasive fungal infections. BMC Infect Dis. 2017;17(1):798.
   PubMedGoogle Scholar
• Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–769.
   PubMed Web of Science ®Google Scholar
• DiPippo AJ, Rausch CR, Kontoyiannis DP. Tolerability of isavuconazole after posaconazole toxicity in leukaemia patients. Mycoses. 2019;62(1):81–86.
   PubMed Web of Science ®Google Scholar
• European Medicines Agency Guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease. 2010.
   Google Scholar
• Marty FM, Ostrosky-Zeichner L, Cornely OA, et al. Isavuconazole treatment for mucormycosis: a single-arm open-label trial and case-control analysis. Lancet Infect Dis. 2016;16(7):828–837.
   PubMed Web of Science ®Google Scholar
• Bose P, McCue D, Wurster S, et al. Isavuconazole as primary anti-fungal prophylaxis in patients with acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective, phase II study. Clin Infect Dis. 2021;72(10):1755–1763.
   PubMed Web of Science ®Google Scholar
• Cornely OA, Böhme A, Schmitt-Hoffmann A, et al. Safety and pharmacokinetics of isavuconazole as antifungal prophylaxis in acute myeloid leukemia patients with neutropenia: results of a phase 2, dose escalation study. Antimicrob Agents Chemother. 2015;59(4):2078–2085.
   PubMed Web of Science ®Google Scholar
• Stern A, Su Y, Lee YJ, et al. A single-center, open-label trial of isavuconazole prophylaxis against invasive fungal infection in patients undergoing allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2020;26(6):1195–1202.
   PubMed Web of Science ®Google Scholar
• Cupri A, Leotta S, Markovic U, et al. Isavuconazole prophylaxis during early phases of allogeneic HSC transplantation is not associated to an increase need of cyclosporin-a dose modification. Blood. 2019;134(Suppl 1):3271.
   Google Scholar
• Aldoss I, Dadwal S, Zhang J, et al. Invasive fungal infections in acute myeloid leukemia treated with venetoclax and hypomethylating agents. Blood Adv. 2019;3(23):4043–4049.
   PubMed Web of Science ®Google Scholar
• Samanta P, Clancy CJ, Marini RV, et al. Isavuconazole is as effective as and better tolerated than voriconazole for antifungal prophylaxis in lung transplant recipients. Clin Infect Dis. 2021;73(3):416–426.
   PubMed Web of Science ®Google Scholar
• Bowen CD, Tallman GB, Hakki M, et al. Isavuconazole to prevent invasive fungal infection in immunocompromised adults: initial experience at an academic medical centre. Mycoses. 2019;62(8):665–672.
   PubMed Web of Science ®Google Scholar
• Fontana L, Perlin DS, Zhao Y, et al. Isavuconazole prophylaxis in patients with hematologic malignancies and hematopoietic cell transplant recipients. Clin Infect Dis. 2020;70(5):723–730.
   PubMed Web of Science ®Google Scholar
• Vu CA, Rana MM, Jacobs SE, et al. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience. Transpl Infect Dis. 2020;23(2):e13469.
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Care Excellence Single technology appraisal: user guide for company evidence submission template. 2015.
   Google Scholar
• Wells GA, Shea B, O’Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2021.
   Google Scholar
• Bogler Y, Stern A, Su Y, et al. Efficacy and safety of isavuconazole compared with voriconazole as primary antifungal prophylaxis in allogeneic hematopoietic cell transplant recipients [published online ahead of print May 24, 2021]. Med Mycol; doi:10.1093/mmy/myab025.
   Google Scholar
• Klatt ME, Eschenauer GA. Review of pharmacologic considerations in the use of azole antifungals in lung transplant recipients. J Fungi (Basel). 2021;7(2):76.
   PubMedGoogle Scholar
• Tragiannidis A, Gkampeta A, Vousvouki M, et al. Antifungal agents and the kidney: pharmacokinetics, clinical nephrotoxicity, and interactions [published online ahead of print June 1, 2021]. Expert Opin Drug Saf; doi:10.1080/14740338.2021.
   Google Scholar